Detailed behavioral assessment promotes accurate diagnosis in patients with disorders of consciousness.

INTRODUCTION: Assessing the awareness level in patients with disorders of consciousness (DOC) is made on the basis of exhibited behaviors. However, since motor signs of awareness (i.e., non-reflex motor responses) can be very subtle, differentiating the vegetative from minimally conscious states (which is in itself not clear-cut) is often challenging. Even the careful clinician relying on standardized scales may arrive at a wrong diagnosis. AIM: To report our experience in tackling this problem by using two in-house use assessment procedures developed at Reuth Rehabilitation Hospital, and demonstrate their clinical significance by reviewing two cases. METHODS: (1) Reuth DOC Response Assessment (RDOC-RA) -administered in addition to the standardized tools, and emphasizes the importance of assessing a wide range of motor responses. In our experience, in some patients the only evidence for awareness may be a private specific movement that is not assessed by standard assessment tools. (2) Reuth DOC Periodic Intervention Model (RDOC-PIM) - current literature regarding assessment and diagnosis in DOC refers mostly to the acute phase of up to 1 year post injury. However, we have found major changes in responsiveness occurring 1 year or more post-injury in many patients. Therefore, we conduct periodic assessments at predetermined times points to ensure patients are not misdiagnosed or neurological changes overlooked. RESULTS: In the first case the RDOC-RA promoted a more accurate diagnosis than that based on standardized scales alone. The second case shows how the RDOC-PIM allowed us to recognize late recovery and promoted reinstatement of treatment with good results. CONCLUSION: Adding a detailed periodic assessment of DOC patients to existing scales can yield critical information, promoting better diagnosis, treatment, and clinical outcomes. We discuss the implications of this observation for the future development and validation of assessment tools in DOC patients.

Cerebral vasomotor reactivity of patients with acute ischemic stroke: Cortical versus subcortical infarcts: an Israeli-Turkish collaborative study.

BACKGROUND: Cerebral hemodynamic features of patients with different types of acute ischemic stroke are still obscure. We compared cerebral vasomotor reactivity (VMR) in acute cortical (CI) and subcortical (SI) brain infarcts. METHODS: Acute stroke patients (within 72 h of stroke onset) underwent transcranial Doppler and the Diamox test (1 g acetazolamide IV). The percent difference between blood flow velocities in the middle cerebral arteries before and after acetazolamide was defined as VMR%. CI and SI infarcts were confirmed by computerized tomography and/or magnetic resonance imaging. Clinical status and disability were assessed by means of the National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) respectively.VMR% values and stroke severity and disability parameters were compared between CI and SI groups using ANOVA and Pearson's correlation (r) coefficients. RESULTS: VMR% values of the ipsilateral side to the brain infarct in the CI group were significantly lower as compared with SI group (12.2+/-15.9% and 25.6+/-24.4% respectively, P=0.03). VMR% values in both groups were not correlated with stroke severity and disability (P<0.2). CONCLUSIONS: Our results suggest greater vulnerability of resistance arterioles in the setting of cortical gray matter infarcts. Although gray matter VMR is physiologically higher than white matter VMR, patients with acute CI have impaired cerebral vascular reserve.

Angiographic results of the first human experience with everolimus-eluting stents for the treatment of coronary lesions (the FUTURE I trial).

The purpose of this study was to report the angiographic findings of the first human evaluation of the everolimus-eluting stent (EES) for the treatment of noncomplex coronary lesions. Forty-two patients with de novo coronary lesions (2.75 to 4.00 mm vessels; lesion length, <18 mm) were prospectively randomized in a 2:1 ratio to receive either the EES (n = 27) or a metallic stent (n = 15). Baseline clinical and angiographic characteristics were similar among both groups. At 6-month follow-up, EES had a lower in-stent late lumen loss (0.10 +/- 0.22 vs 0.85 +/- 0.32 mm, p <0.0001) and in-segment diameter stenoses (20.7 +/- 12.3% vs 37.0 +/- 15.8%, p = 0.002). There was no in-stent restenosis with EES; however, 1 focal distal edge restenosis was present. There was 1 in-stent and 1 in-segment (proximal edge) restenosis in the metallic stent group. There was no stent thrombosis or aneurysm formation at follow-up in either group.